Secukinumab for plaque psoriasis

被引:2
|
作者
Ordenes-Cavieres, Gonzalo [1 ,2 ]
Andino-Navarrete, Romina [2 ,3 ]
机构
[1] Pontificia Univ Catolica Chile, Fac Med, Santiago, Chile
[2] Proyecto Epistemon, Santiago, Chile
[3] Pontificia Univ Catolica Chile, Fac Med, Dept Dermatol, Santiago, Chile
来源
MEDWAVE | 2018年 / 18卷 / 07期
关键词
Plaque psoriasis; biological treatments; secukinumab; Epistemonikos; GRADE;
D O I
10.5867/medwave.2018.07.7363
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Biological treatments have appeared as the main alternative for the management of patients with plaque psoriasis that do not respond to conventional treatment. So, evaluating its actual efficacy and safety is needed. Methods We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. Results and conclusions We identified 21 systematic reviews including ten studies overall, of which all were randomized trials. We concluded secukinumab achieves clinical improvement in patients with plaque psoriasis, although it is probably associated with serious adverse effects.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Paradoxical plaque psoriasis due to secukinumab treatment in an ankylosing spondylitis patient
    Durmaz, Koray
    Ataseven, Arzu
    Ozer, Ilkay
    DERMATOLOGIC THERAPY, 2020, 33 (04)
  • [32] Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis
    Wong, Ian T. Y.
    Shojania, Kam
    Dutz, Jan
    Tsao, Nicole W.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 153 - 166
  • [33] Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis
    Cao, Zhiqiang
    Liu, Zhaoyang
    Zhu, Xia
    Yang, Qinbo
    Xu, Qingqing
    Zhang, Chunhong
    RENAL FAILURE, 2022, 44 (01) : 826 - 830
  • [34] Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
    Zhang Si
    Cai Lin
    Zhang Heng
    Zhao Zheng
    Liu Xiaoyang
    Zhao Yan
    Zhang Jianzhong
    中华医学杂志英文版, 2022, 135 (18)
  • [35] Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 173 - 178
  • [36] Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis
    Pinter, A.
    Gerdes, S.
    Hacker, E.
    Reinhardt, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 114 - 115
  • [37] Secukinumab for Recalcitrant Chronic Plaque Psoriasis in a 9 Year Old Child
    Shruthi, R.
    Criton, Sebastian
    INDIAN JOURNAL OF DERMATOLOGY, 2021, 66 (05) : 575
  • [38] Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
    Gisondi P.
    Dalle Vedove C.
    Girolomoni G.
    Dermatology and Therapy, 2014, 4 (1) : 1 - 9
  • [39] Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
    Zhang, Si
    Cai, Lin
    Zhang, Heng
    Zhao, Zheng
    Liu, Xiaoyang
    Zhao, Yan
    Zhang, Jianzhong
    CHINESE MEDICAL JOURNAL, 2022, 135 (18) : 2248 - 2250
  • [40] Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis
    Pinter, Andreas
    Gerdes, Sascha
    Papavassilis, Charis
    Reinhardt, Maximilian
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (08) : 769 - 775